Shifting Identities: How Lung Cancer Cells Change Face to Outsmart Treatment

Small-cell lung cancer has long been one of oncology’s most punishing adversaries. It grows with astonishing speed, spreads early, and presents a treatment paradox that has frustrated clinicians for decades: at diagnosis, tumors melt away under platinum-based chemotherapy, yet relapse is nearly universal, and the disease that returns is almost always resistant. A new review published in Clinical Cancer Bulletin argues that the answer to this stubborn pattern lies not primarily in fresh genetic mutations, but in something far stranger—the ability of cancer cells to abandon their own identity and re-emerge in a different molecular guise.

The phenomenon is called lineage infidelity, and it describes a form of cellular plasticity in which small-cell lung cancer cells transition between molecularly distinct states to evade both physiological pressures and therapeutic attack. Historically, the disease was viewed as a single, uniform neuroendocrine tumor. Modern genomic and transcriptomic profiling has dismantled that view entirely, revealing at least four major molecular subtypes defined by the dominant activity of key transcription factors: ASCL1 in the SCLC-A subtype, NEUROD1 in SCLC-N, POU2F3 in SCLC-P, and YAP1 marking a mesenchymal-like, non-neuroendocrine phenotype often called SCLC-Y. The status of YAP1 as a true lineage-defining factor remains debated among researchers, but its value as a marker of therapeutic escape is widely accepted.

Crucially, these states are not fixed. They represent fluid points along a phenotypic spectrum, allowing tumors to shift identities as conditions change. A tumor that begins as a highly neuroendocrine SCLC-A malignancy may transition toward a non-neuroendocrine or inflamed state when treatment targets its original vulnerabilities, effectively changing molecular camouflage mid-course. Single-cell RNA sequencing and genetically engineered mouse models have been instrumental in mapping these transitions, showing that they are governed less by new mutations and more by an epigenetic rheostat—a dynamic, reversible control system of gene expression built on chromatin remodeling and lineage-specific enhancers.

The mechanistic details are striking. The best-characterized switch occurs between the SCLC-A and SCLC-N states, both neuroendocrine but occupying distinct regulatory territories. Activation of NOTCH signaling induces the expression of HES1, which directly represses ASCL1, facilitating movement toward NEUROD1-positive or non-neuroendocrine phenotypes. In SCLC-A cells, ASCL1 acts as a pioneer factor keeping chromatin accessible at its target genes; when epigenetic co-factors such as LSD1 are perturbed, methylation marks at H3K4 and H3K9 change, effectively erasing the cell’s transcriptional memory and opening the door to alternative identities. MYC amplification can drive further progression, pushing cells from ASCL1-dominant states through NEUROD1-high states and ultimately toward YAP1-driven mesenchymal phenotypes.

Perhaps the most clinically consequential observation concerns the SCLC-I, or inflamed, subtype, which recent evidence suggests may be a common evolutionary endpoint for tumors treated with chemotherapy. This transition involves a global decrease in DNA methylation that activates endogenous retroviruses and triggers interferon signaling, supporting the shift toward an inflamed phenotype. Meanwhile, the tumor microenvironment supplies external cues that flip internal switches: hypoxia within the tumor core stabilizes HIF-1α, which downregulates neuroendocrine markers and promotes a migratory, mesenchymal-like state. Chemotherapy itself, beyond killing sensitive clones, induces stress responses that can push surviving cells into quiescent or variant states—raising the uncomfortable possibility that standard care may inadvertently steer tumors toward more recalcitrant identities.

But the review’s authors argue that this plasticity is not merely a survival strategy; it is also a weapon clinicians can turn against the tumor. Because every lineage transition opens a new window of vulnerability, they propose a ‘Push-and-Pull’ strategy of evolutionary steering. In the ‘Push’ phase, epigenetic modifiers such as LSD1 inhibitors destabilize the dominant lineage, inducing ASCL1-high neuroendocrine cells to lose their identity and transition toward a more inflamed or non-neuroendocrine state. In the ‘Pull’ phase, a second agent lethally targets the newly acquired state. If the Push produces an inflamed SCLC-I phenotype, the Pull would be immune checkpoint blockade, which is significantly more effective in that molecular context.

Subtype-specific vulnerabilities provide the ammunition for the Pull. Tumors transitioning from SCLC-A/N states toward SCLC-P develop a profound dependence on the DNA damage response, driven by replication stress from MYC or POU2F3 activity, making them hypersensitive to PARP and ATR inhibitors. Cells adopting a YAP1-high mesenchymal phenotype often upregulate the surface marker TROP2, and clinical trials are now investigating TROP2-targeted antibody-drug conjugates for patients whose tumors have undergone this transition—effectively converting a resistance mechanism into a delivery system for chemotherapy. Epigenetic agents such as HDAC or EZH2 inhibitors may even reset the chromatin landscape of resistant non-neuroendocrine cells, reverting them to a neuroendocrine state in which they regain sensitivity to original platinum regimens, a concept known as chemo-resensitization.

Implementing these strategies in the clinic is far from straightforward. Small-cell lung cancer rarely exists as a single pure subtype; high-resolution single-cell mapping shows that most clinical samples are composite tumors containing multiple subtypes in varying proportions. Treating the dominant clone often triggers explosive expansion of a pre-existing minor subclone, and distinguishing clonal selection from true transdifferentiation is essential, because the two demand different interventions. Real-time monitoring is therefore central to the entire framework: longitudinal analysis of circulating tumor DNA and circulating tumor cells can detect molecular signatures of a subtype switch—such as rising POU2F3 or YAP1 fragments, or shifts in subtype-specific DNA methylation patterns—months before imaging reveals tumor growth, allowing preemptive therapeutic pivots while disease burden remains low.

Pharmacological hurdles compound the challenge. HDAC inhibitors like vorinostat and EZH2 inhibitors like tazemetostat are FDA-approved for other malignancies, but their efficacy in small-cell lung cancer remains confined to early-phase trials. LSD1 inhibitors such as iadademstat have shown early promise but are not yet standard of care. Concurrent administration of epigenetic Push agents and cytotoxic Pull agents often produces prohibitive toxicities, including severe myelosuppression and gastrointestinal distress, because chromatin modifiers exert broad transcriptional effects. Sequential targeting mitigates toxicity but demands precise, validated liquid biopsy biomarkers that do not yet fully exist in clinical form. Overcoming these barriers, the authors suggest, will require more selective epigenetic tools such as PROTACs and dynamic trial designs that use ctDNA to trigger therapy switches before relapse becomes visible.

What emerges from this synthesis is a fundamentally new vision for treating one of medicine’s deadliest cancers. Rather than reacting to resistance after it appears, oncologists of the future may proactively direct tumor trajectories toward therapeutic dead ends—luring cancer cells into states where their acquired vulnerabilities become lethal traps. Preclinical platforms including genetically engineered mouse models, patient-derived xenografts, and organoids are already providing the testing grounds for such interventions, and precision immunotherapy approaches aim to extend the benefits of immune checkpoint inhibitors to cold tumors through epigenetic priming. If the capacity for change is the tumor’s greatest strength, the reviewers contend, it may also prove to be its ultimate undoing—transforming small-cell lung cancer from a recalcitrant malignancy into a disease that is manageable, and perhaps one day curable.

Subject of Research: Lineage infidelity and subtype plasticity driving chemoresistance in small-cell lung cancer

Article Title: Lineage infidelity in small-cell lung cancer: driving subtype transitions and acquired therapeutic vulnerabilities

Article References: Ajeh, I. J., Ikukpla’si, O. S. I., Bisoye, D. A., & Danraka, A. (2026). Lineage infidelity in small-cell lung cancer: driving subtype transitions and acquired therapeutic vulnerabilities. Clinical Cancer Bulletin, 5(1), Article 9. https://doi.org/10.1007/s44272-026-00061-7

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00061-7

Keywords: small-cell lung cancer, lineage infidelity, ASCL1, NEUROD1, POU2F3, YAP1, epigenetic reprogramming, tumor plasticity, chemoresistance, Push-and-Pull strategy, liquid biopsy, immune checkpoint blockade